Rapid and sustained improvements in itch and quality of life with upadacitinib plus topical corticosteroids in adults and adolescents with atopic dermatitis: 52-week outcomes from the phase 3 AD Up study

References

• Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):1–10. doi: 10.1016/s0140-6736(20)31286-1.
   PubMed Web of Science ®Google Scholar
• Laughter MR, Maymone MBC, Mashayekhi S, et al. The global burden of atopic dermatitis: lessons from the global burden of disease study 1990–2017. Br J Dermatol. 2021;184(2):304–309. doi: 10.1111/bjd.19580.
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Gelfand JM, Margolis DJ, et al. Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study. Ann Allergy Asthma Immunol. 2018;121(3):340–347. doi: 10.1016/j.anai.2018.07.006.
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Garg NK, Paller AS, et al. Sleep disturbances in adults with eczema are associated with impaired overall health: a US population-based study. J Invest Dermatol. 2015;135(1):56–66. doi: 10.1038/jid.2014.325.
   PubMed Web of Science ®Google Scholar
• Rønnstad ATM, Halling-Overgaard AS, Hamann CR, et al. Association of atopic dermatitis with depression, anxiety, and suicidal ideation in children and adults: a systematic review and meta-analysis. J Am Acad Dermatol. 2018;79(3):448–456.e430. doi: 10.1016/j.jaad.2018.03.017.
   PubMed Web of Science ®Google Scholar
• Barrett A, Hahn-Pedersen J, Kragh N, et al. Patient-reported outcome measures in atopic dermatitis and chronic hand eczema in adults. Patient. 2019;12(5):445–459. doi: 10.1007/s40271-019-00373-y.
   PubMedGoogle Scholar
• Copley-Merriman C, Zelt S, Clark M, et al. Impact of measuring patient-reported outcomes in dermatology drug development. Patient. 2017;10(2):203–213. doi: 10.1007/s40271-016-0196-6.
   PubMedGoogle Scholar
• Williams HC, Schmitt J, Thomas KS, et al. The HOME core outcome set for clinical trials of atopic dermatitis. J Allergy Clin Immunol. 2022;149(6):1899–1911. doi: 10.1016/j.jaci.2022.03.017.
   PubMed Web of Science ®Google Scholar
• de Bruin-Weller M, Biedermann T, Bissonnette R, et al. Treat-to-target in atopic dermatitis: an international consensus on a set of core decision points for systemic therapies. Acta Derm Venereol. 2021;101(2):adv00402. doi: 10.2340/00015555-3751.
   PubMedGoogle Scholar
• de Bruin-Weller M, Deleuran M, Biedermann T, et al. The treat-to-target project in atopic dermatitis: one year on. Acta Derm Venereol. 2023;103:adv5382. doi: 10.2340/actadv.v103.5382.
   PubMed Web of Science ®Google Scholar
• Leshem YA, Chalmers JR, Apfelbacher C, et al. Measuring atopic eczema symptoms in clinical practice: the first consensus statement from the harmonising outcome measures for eczema in clinical practice initiative. J Am Acad Dermatol. 2020;82(5):1181–1186. doi: 10.1016/j.jaad.2019.12.055.
   PubMed Web of Science ®Google Scholar
• Leshem YA, Chalmers JR, Apfelbacher C, et al. Measuring atopic eczema control and itch intensity in clinical practice: a consensus statement from the harmonising outcome measures for eczema in clinical practice (HOME-CP) initiative. JAMA Dermatol. 2022;158(12):1429–1435. doi: 10.1001/jamadermatol.2022.4211.
   PubMed Web of Science ®Google Scholar
• Silverberg J, Gooderham M, Katoh N, et al. Optimizing the management of atopic dermatitis with a new minimal disease activity concept and criteria and consensus-based recommendations for systemic therapy. Br J Dermatol. 2023;188(Supp 2):ljac140-022. doi: 10.1093/bjd/ljac140.022.
   Web of Science ®Google Scholar
• RINVOQ. Prescribing information. North Chicago (Ill): AbbVie; 2022. [cited 2024 Feb 06]. https://www.rxabbvie.com/pdf/rinvoq_pi.pdf.
   Google Scholar
• RINVOQ. Summary of Product Characteristics. AbbVie Deutschland GmbH & Co. KG; 2023 [cited 2023 April 24]. https://www.ema.europa.eu/en/documents/product-information/rinvoq-epar-product-information_en.pdf.
   Google Scholar
• Parmentier JM, Voss J, Graff C, et al. In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). BMC Rheumatol. 2018;2(1):23. doi: 10.1186/s41927-018-0031-x.
   PubMedGoogle Scholar
• Guttman-Yassky E, Teixeira HD, Simpson EL, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (measure up 1 and measure up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. 2021;397(10290):2151–2168. doi: 10.1016/s0140-6736(21)00588-2.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Papp KA, Blauvelt A, et al. Efficacy and safety of upadacitinib in patients with moderate to severe atopic dermatitis: analysis of follow-up data from the measure up 1 and measure up 2 randomized clinical trials. JAMA Dermatol. 2022;158(4):404–413. doi: 10.1001/jamadermatol.2022.0029.
   PubMed Web of Science ®Google Scholar
• Silverberg JI, de Bruin-Weller M, Bieber T, et al. Upadacitinib plus topical corticosteroids in atopic dermatitis: week 52 AD up study results. J Allergy Clin Immunol. 2022;149(3):977–987.e914. doi: 10.1016/j.jaci.2021.07.036.
   PubMed Web of Science ®Google Scholar
• Reich K, Teixeira HD, de Bruin-Weller M, et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2021;397(10290):2169–2181. doi: 10.1016/s0140-6736(21)00589-4.
   PubMed Web of Science ®Google Scholar
• He H, Guttman-Yassky E. JAK inhibitors for atopic dermatitis: an update. Am J Clin Dermatol. 2019;20(2):181–192. doi: 10.1007/s40257-018-0413-2.
   PubMed Web of Science ®Google Scholar
• Han Y, Woo YR, Cho SH, et al. Itch and Janus kinase inhibitors. Acta Derm Venereol. 2023;103:adv00869. doi: 10.2340/actadv.v103.5346.
   PubMed Web of Science ®Google Scholar
• Charman CR, Venn AJ, Williams HC. The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients’ perspective. Arch Dermatol. 2004;140(12):1513–1519. doi: 10.1001/archderm.140.12.1513.
   PubMedGoogle Scholar
• Finlay AY, Khan GK. Dermatology life quality index (DLQI)–a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210–216. doi: 10.1111/j.1365-2230.1994.tb01167.x.
   PubMed Web of Science ®Google Scholar
• Foley C, Tundia N, Simpson E, et al. Development and content validity of new patient-reported outcome questionnaires to assess the signs and symptoms and impact of atopic dermatitis: the atopic dermatitis symptom scale (ADerm-SS) and the atopic dermatitis impact scale (ADerm-is). Curr Med Res Opin. 2019;35(7):1139–1148. doi: 10.1080/03007995.2018.1560222.
   PubMed Web of Science ®Google Scholar
• Reich K, de Bruin-Weller MS, Deleuran M, et al. Higher levels of response on clinical atopic dermatitis severity measures are associated with meaningful improvements in patient-reported symptom and quality of life measures: integrated analysis of three upadacitinib phase 3 trials. J Eur Acad Dermatol Venereol. 2023;37(8):1634–1641. doi: 10.1111/jdv.18995.
   Web of Science ®Google Scholar
• Silverberg JI, Simpson EL, Calimlim BM, et al. Determining severity strata for three atopic dermatitis patient-reported outcome questionnaires: defining severity score ranges for the worst pruritus numerical rating scale and the atopic dermatitis symptom and impact scales (ADerm-SS and ADerm-is). Dermatol Ther. 2022;12(12):2817–2827. doi: 10.1007/s13555-022-00836-5.
   Web of Science ®Google Scholar
• Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361–370. doi: 10.1111/j.1600-0447.1983.tb09716.x.
   PubMed Web of Science ®Google Scholar
• NIMH. Patient global impressions scale – Change, improvement, severity (PGI-C, PGI-I, PGI-S). 2023. https://eprovide.mapi-trust.org/instruments/patient-global-impressions-scale-change-improvement-severity.
   Google Scholar
• Carroll CL, Balkrishnan R, Feldman SR, et al. The burden of atopic dermatitis: impact on the patient, family, and society. Pediatr Dermatol. 2005;22(3):192–199. doi: 10.1111/j.1525-1470.2005.22303.x.
   PubMed Web of Science ®Google Scholar
• Drucker AM, Wang AR, Li WQ, et al. The burden of atopic dermatitis: summary of a report for the national eczema association. J Invest Dermatol. 2017;137(1):26–30. doi: 10.1016/j.jid.2016.07.012.
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Chiesa-Fuxench Z, Margolis D, et al. Epidemiology and burden of sleep disturbances in atopic dermatitis in US adults. Dermatitis. 2022;33(6S):S104–s113. doi: 10.1097/der.0000000000000731.
   PubMed Web of Science ®Google Scholar
• Bawany F, Northcott CA, Beck LA, et al. Sleep disturbances and atopic dermatitis: relationships, methods for assessment, and therapies. J Allergy Clin Immunol Pract. 2021;9(4):1488–1500. doi: 10.1016/j.jaip.2020.12.007.
   PubMed Web of Science ®Google Scholar